(VIANEWS) – The NASDAQ ended the session with Viking Therapeutics (VKTX) rising 13.66% to $36.20 on Monday while NASDAQ dropped 0.82% to $15,775.65.
Viking Therapeutics’s last close was $36.20, 2.74% below its 52-week high of $37.22.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.79%.
Yearly Top and Bottom Value
Viking Therapeutics’s stock is valued at $36.20 at 17:04 EST, under its 52-week high of $37.22 and way above its 52-week low of $8.28.
More news about Viking Therapeutics (VKTX).
